Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05489614 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Participants With Normal Renal Function and Participants With Various Degrees of Renal Impairment
A Phase 1 study of Renal Impairment, sponsored by Amgen.
- Completed
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
- 6
- Study locations
NCT05489614 is a Phase 1 study of Renal Impairment that has completed, run by Amgen. The registered enrollment target is 33 participants, roughly in line with the 34-participant average among 32 other Renal Impairment trials with a reported enrollment target. The trial reports 6 study locations across 3 states.
The verdict
NCT05489614, a Phase 1 study of Renal Impairment, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
- 6
- Study locations
Study Summary
The primary objective of this study is to evaluate the pharmacokinetics (PK) of a single dose of olpasiran in participants with normal renal function and participants with various degrees of renal impairment.
Conditions Studied
Interventions
- DRUG Olpasiran
Study Locations (6)
Florida
- Clinical Pharmacology Of Miami, LLC - Miami
- Advanced Pharma CR, LLC - Miami
- Orlando Clinical Research Center - Orlando
California
- Inland Empire Clinical Trials, LLC - Rialto
- CRSCA HC LLC, dba Creekside Post Acute - Yucaipa
Minnesota
- Nucleus Network - Minneapolis - Saint Paul
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2022-09-13 |
| Est. Completion | 2023-12-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05489614
The ClinicalTrials.gov registry entry for NCT05489614 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 34-participant average among 32 other Renal Impairment trials with a reported enrollment target. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Renal Impairment appearing as the primary indexed condition, and to 1 intervention - of which Olpasiran is the first listed.
NCT05489614 reports 6 study locations spanning 3 distinct geographic areas - top geographies include Florida, California, Minnesota.
Frequently Asked Questions
What is clinical trial NCT05489614 about?
NCT05489614 is a clinical study titled "A Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Participants With Normal Renal Function and Participants With Various Degrees of Renal Impairment". The primary objective of this study is to evaluate the pharmacokinetics (PK) of a single dose of olpasiran in participants with normal renal function and participants with various degrees of renal impairment.
What is the current status of trial NCT05489614?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2022-09-13. Estimated completion is 2023-12-19.
What conditions does trial NCT05489614 study?
This clinical trial studies the following conditions: Renal Impairment.
What interventions are being tested in trial NCT05489614?
The interventions under investigation include: Olpasiran (DRUG).
Who is sponsoring clinical trial NCT05489614?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05489614 being conducted?
This trial has 6 study locations across California, Florida, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Renal Impairment
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic Function
RECRUITING · Phase 1
-
A Study of S-892216-PO in Participants With Renal Impairment and Matched Controls
RECRUITING · Phase 1
-
Investigation of the Effects of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of Opemalirsen (AZD2373)
RECRUITING · Phase 1
-
A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With Reduced Kidney Function
RECRUITING · Phase 1
-
A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal Function
RECRUITING · Phase 1
-
A Clinical Trial of MK-2828 in People With Kidney Disease (MK-2828-006)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.